Following the completion of a Phase II trial of sutacimig, Hemab is preparing to progress to a registration trial in 2026.
The family of a two-year-old boy who has spent most of his life in hospital battling a rare and life-threatening blood ...
Maison has spent most of his life being treated in hospital and currently can not play with other children due to his ...
BioMarin Pharmaceutical said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback